Development of target specific agents for bladder cancer

Josep Domingo-Domenech, Scot Niglio, Matthew D. Galsky

Research output: Contribution to journalReview articlepeer-review


Introduction: There has been a paucity of new therapies developed for the treatment of advanced urothelial cancer due to a convergence of factors including a low prioritization of the disease by industry, therapeutic nihilism, and a limited understanding of the molecular pathogenesis and relevant therapeutic targets. Areas covered: Herein, we review contemporary clinical trials in metastatic urothelial cancer. The review focuses primary on therapeutics directed against somatic genomic alterations, immune checkpoints, and tumor-specific antigen which may serve to selectively deliver cytotoxic payloads (i.e., antibody drug conjugates). Expert commentary: Novel therapeutic approaches have finally established proof of concept in patients with metastatic urothelial cancer. The next few years will witness an expansion of the standard armamentarium and lead to improved outcomes for those suffering with this difficult disease.

Original languageEnglish (US)
Pages (from-to)361-368
Number of pages8
JournalExpert Review of Precision Medicine and Drug Development
Issue number4
StatePublished - Jul 3 2016


  • Head and neck cancer
  • personalized medicine
  • precision medicine
  • targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Development of target specific agents for bladder cancer'. Together they form a unique fingerprint.

Cite this